wild type rbd Search Results


genlisa sars cov 2 covid 19 surrogate virus neutralization test surrogate virus neutralization test svnt elisa  (Krishgen Biosystems)
93
Krishgen Biosystems genlisa sars cov 2 covid 19 surrogate virus neutralization test surrogate virus neutralization test svnt elisa
Genlisa Sars Cov 2 Covid 19 Surrogate Virus Neutralization Test Surrogate Virus Neutralization Test Svnt Elisa, supplied by Krishgen Biosystems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wild+type+rbd/pmc09501048-121-3-12?v=Krishgen+Biosystems
Average 93 stars, based on 1 article reviews
genlisa sars cov 2 covid 19 surrogate virus neutralization test surrogate virus neutralization test svnt elisa - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
horseradish peroxidase (hrp)–rbd wild-type  (GenScript corporation)
90
GenScript corporation horseradish peroxidase (hrp)–rbd wild-type
Horseradish Peroxidase (Hrp)–Rbd Wild Type, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wild+type+rbd/pmc10973674-95-5-6?v=GenScript+corporation
Average 90 stars, based on 1 article reviews
horseradish peroxidase (hrp)–rbd wild-type - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
wild type hrpo-conjugated rbd  (GenScript corporation)
90
GenScript corporation wild type hrpo-conjugated rbd
Wild Type Hrpo Conjugated Rbd, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wild+type+rbd/ppr0606560-66-2-19?v=GenScript+corporation
Average 90 stars, based on 1 article reviews
wild type hrpo-conjugated rbd - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
recombinant rbd wild-type  (LakePharma)
90
LakePharma recombinant rbd wild-type
Recombinant Rbd Wild Type, supplied by LakePharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wild+type+rbd/us11213581-614-7-10?v=LakePharma
Average 90 stars, based on 1 article reviews
recombinant rbd wild-type - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
wild-type rbd  (BEI Resources)
90
BEI Resources wild-type rbd
a Serum antibody levels (EC50) that recognize the spike <t>RBD</t> of the <t>wild-type</t> USA-WA1/2020 (WA1) (Blue circles), B.1.1.7 (Orange squares), and B.1.351 (Green triangles) variants are shown. The RBD-B.1.1.7 carries the N501Y mutation, the only RBD mutation present in the B.1.1.7 variant. The RBD-B.1.351 has the K417N, E484K, and N501Y mutations which are the only three RBD mutations present in the B.1.351 variant. n = 51 biologically independent samples. b Comparison of neutralization titers (FRNT50) between WA1, B.1.1.7 ( P = 0.0351) and B.1.351 ( P = 0.0089) for BNT162b2 vaccinee sera. n = 50 biologically independent samples. c Correlation of variant matched RBD-specific antibody levels and neutralization titers (FRNT50) of the WA1 virus and the two variants. d , e Correlations between neutralization titers of the B.1.1.7 ( d ) and B.1.351 ( e ) variants with the WA1 virus. The dotted diagonal lines indicate identical neutralization, and the solid diagonal black lines indicate 10-fold differences in neutralization. f – h Correlation between participant age and neutralization titer against WA1 ( f ) ( P < 0.0001), B.1.1.7 ( g ) ( P < 0.0001), and B.1.351 ( h ) ( P < 0.0001). n = 50 biologically independent samples. i Effect of age range 20–50 years (blue triangle) and >50 years (red inverted triangle) on the neutralization potency among the BNT162b2 vaccine recipients (WA1,B.1.1.7 P < 0.0001, B.1.351 P = 0.0001). n = 25 biologically independent samples per age group. For a , b , f – i , data are presented as the mean ± SD of log transformed values; P values are two-sided and include a Šidák multiple comparison correction. All experiments were performed in duplicate.
Wild Type Rbd, supplied by BEI Resources, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/wild+type+rbd/pmc08390486-129-8-10?v=BEI+Resources
Average 90 stars, based on 1 article reviews
wild-type rbd - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
sars-cov-2 (wild type+south african variant) rbd antigen quantitative titration elisa  (Eagle Biosciences)
N/A
SARS-CoV-2 (Wild Type+South African Variant) RBD Antigen Quantitative TITRATION ELISA
   Buy from Supplier

Image Search Results


a Serum antibody levels (EC50) that recognize the spike RBD of the wild-type USA-WA1/2020 (WA1) (Blue circles), B.1.1.7 (Orange squares), and B.1.351 (Green triangles) variants are shown. The RBD-B.1.1.7 carries the N501Y mutation, the only RBD mutation present in the B.1.1.7 variant. The RBD-B.1.351 has the K417N, E484K, and N501Y mutations which are the only three RBD mutations present in the B.1.351 variant. n = 51 biologically independent samples. b Comparison of neutralization titers (FRNT50) between WA1, B.1.1.7 ( P = 0.0351) and B.1.351 ( P = 0.0089) for BNT162b2 vaccinee sera. n = 50 biologically independent samples. c Correlation of variant matched RBD-specific antibody levels and neutralization titers (FRNT50) of the WA1 virus and the two variants. d , e Correlations between neutralization titers of the B.1.1.7 ( d ) and B.1.351 ( e ) variants with the WA1 virus. The dotted diagonal lines indicate identical neutralization, and the solid diagonal black lines indicate 10-fold differences in neutralization. f – h Correlation between participant age and neutralization titer against WA1 ( f ) ( P < 0.0001), B.1.1.7 ( g ) ( P < 0.0001), and B.1.351 ( h ) ( P < 0.0001). n = 50 biologically independent samples. i Effect of age range 20–50 years (blue triangle) and >50 years (red inverted triangle) on the neutralization potency among the BNT162b2 vaccine recipients (WA1,B.1.1.7 P < 0.0001, B.1.351 P = 0.0001). n = 25 biologically independent samples per age group. For a , b , f – i , data are presented as the mean ± SD of log transformed values; P values are two-sided and include a Šidák multiple comparison correction. All experiments were performed in duplicate.

Journal: Nature Communications

Article Title: Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

doi: 10.1038/s41467-021-25479-6

Figure Lengend Snippet: a Serum antibody levels (EC50) that recognize the spike RBD of the wild-type USA-WA1/2020 (WA1) (Blue circles), B.1.1.7 (Orange squares), and B.1.351 (Green triangles) variants are shown. The RBD-B.1.1.7 carries the N501Y mutation, the only RBD mutation present in the B.1.1.7 variant. The RBD-B.1.351 has the K417N, E484K, and N501Y mutations which are the only three RBD mutations present in the B.1.351 variant. n = 51 biologically independent samples. b Comparison of neutralization titers (FRNT50) between WA1, B.1.1.7 ( P = 0.0351) and B.1.351 ( P = 0.0089) for BNT162b2 vaccinee sera. n = 50 biologically independent samples. c Correlation of variant matched RBD-specific antibody levels and neutralization titers (FRNT50) of the WA1 virus and the two variants. d , e Correlations between neutralization titers of the B.1.1.7 ( d ) and B.1.351 ( e ) variants with the WA1 virus. The dotted diagonal lines indicate identical neutralization, and the solid diagonal black lines indicate 10-fold differences in neutralization. f – h Correlation between participant age and neutralization titer against WA1 ( f ) ( P < 0.0001), B.1.1.7 ( g ) ( P < 0.0001), and B.1.351 ( h ) ( P < 0.0001). n = 50 biologically independent samples. i Effect of age range 20–50 years (blue triangle) and >50 years (red inverted triangle) on the neutralization potency among the BNT162b2 vaccine recipients (WA1,B.1.1.7 P < 0.0001, B.1.351 P = 0.0001). n = 25 biologically independent samples per age group. For a , b , f – i , data are presented as the mean ± SD of log transformed values; P values are two-sided and include a Šidák multiple comparison correction. All experiments were performed in duplicate.

Article Snippet: Site-directed mutagenesis was used to introduce mutations into Wild-type RBD (BEI resources #NR-52309).

Techniques: Mutagenesis, Variant Assay, Neutralization, Transformation Assay

a Quantification of serum antibody levels (EC50) that recognize RBD protein corresponding to the wild-type (WA1)(blue circles), B.1.1.7 (orange squares), and B.1.351 (green triangles) variants. n = 50 biologically independent samples. Data are presented as the mean ± SD of log transformed values. b Comparison of neutralization titers between WA1, B.1.1.7, and B.1.351 for convalescent sera. n = 44 biologically independent samples. c Relationship between convalescent antibody levels and neutralization (FRNT50) of the different viral variants. d , e Correlations between convalescent serum neutralization titer of the B.1.1.7 ( d ) and B.1.351 ( e ) variants with the WA1 virus. The dotted diagonal lines indicate identical neutralization, and the solid diagonal black lines indicate 10-fold differences in neutralization. f Violin plots indicating FRNT50 values for WA1 (blue), B.1.1.7 (orange), and B.1.351 (green), stratified by the number of days between the date of confirmatory COVID-19 PCR test and the date of serum sample collection. Black bars indicate median FRNT50 for each group. For a , b , f P values are two-sided and include a Šidák multiple comparison correction. All experiments were performed in duplicate.

Journal: Nature Communications

Article Title: Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum

doi: 10.1038/s41467-021-25479-6

Figure Lengend Snippet: a Quantification of serum antibody levels (EC50) that recognize RBD protein corresponding to the wild-type (WA1)(blue circles), B.1.1.7 (orange squares), and B.1.351 (green triangles) variants. n = 50 biologically independent samples. Data are presented as the mean ± SD of log transformed values. b Comparison of neutralization titers between WA1, B.1.1.7, and B.1.351 for convalescent sera. n = 44 biologically independent samples. c Relationship between convalescent antibody levels and neutralization (FRNT50) of the different viral variants. d , e Correlations between convalescent serum neutralization titer of the B.1.1.7 ( d ) and B.1.351 ( e ) variants with the WA1 virus. The dotted diagonal lines indicate identical neutralization, and the solid diagonal black lines indicate 10-fold differences in neutralization. f Violin plots indicating FRNT50 values for WA1 (blue), B.1.1.7 (orange), and B.1.351 (green), stratified by the number of days between the date of confirmatory COVID-19 PCR test and the date of serum sample collection. Black bars indicate median FRNT50 for each group. For a , b , f P values are two-sided and include a Šidák multiple comparison correction. All experiments were performed in duplicate.

Article Snippet: Site-directed mutagenesis was used to introduce mutations into Wild-type RBD (BEI resources #NR-52309).

Techniques: Transformation Assay, Neutralization